

7465 '00 NOV 30 A11:28

November 15, 2000

Jane Henney, M.D.
Commissioner, Food and Drug Administration
Dockets Management Branch
Department of Health and Human Services, Room 1-23
12420 Parklawn Drive
Rockville, MD 20857

RE: Docket No. 00P-1499/CP1

Dear Dr. Henney:

I am a practicing physician in a large group of gastroenterologists in East Lansing, Michigan. As you can well imagine, a large percentage of our practice is caring for those suffering with irritable bowel syndrome. It has been my experience that for years we have been in need of new medications to treat this malady, as it can be often debilitating to our patients.

The development and distribution of Lotronex has been monumental in helping us care for our female patients suffering with diarrhea-predominant irritable bowel syndrome. I have been able to prescribe this medication for several patients with excellent results. Their quality of life has improved significantly. They are no longer "staying at home" for fear of incontinence.

My patients and I have been more than pleased with the release and usage of this product. Should you have any questions or concerns regarding this letter, please do not hesitate to contact me.

Sincerely

Robert P. Rose, D.O., F.A.C.O.I.

RPR:kkb


Dictated but not read.


OOP-1499

C, 26

1650 RAMBLEWOOD DR. SUITE 100 ~ EAST LANSING MI 48823 ~ P 517.332.1200 / 517.351.2340 F 517.351.7122







JANE HENNEY, MD.
COMMISSIONER, FOOD AND DRUG ADMINISTRATION
DOCKETS MANAGEMENT BRANCH
DEPARTMENT OF HEALTH AND HUMAN SERVICES, ROOM 1-23
12420 PARKLAWN DRIVE
ROCKVILLE, MD 20857